Logo

Merck's Keytruda (pembrolizumab) + CT Receives NMPA's approval as 1L Treatment for Metastatic Squamous Non-Small Cell Lung Cancer

Share this
Merck's Keytruda (pembrolizumab) + CT Receives NMPA's approval as 1L Treatment for Metastatic Squamous Non-Small Cell Lung Cancer

Merck's Keytruda (pembrolizumab) + CT Receives NMPA's approval as 1L Treatment for Metastatic Squamous Non-Small Cell Lung Cancer

Shots:

  • The approval is based on P-III KEYNOTE-407 study assessing Keytruda + CT (carboplatin and either paclitaxel or nab-paclitaxel) in patients with metastatic sq. NSCLC and data from the extension of the global study in Chinese patients
  • The P-III KEYNOTE-407 study results: improvement in OS and PFS; 36% reduction in risk of death; 44% reduction in risk of progression. Extension study results: 56% reduction in risk of death; improvement in PFS with a 68% reduction in risk of progression
  • KEYTRUDA is an anti-PD-1 therapy- acts by blocking the interaction between PD-1 and its ligands- PD-L1 and PD-L2 thus activating T lymphocytes affecting both tumor and healthy cells and is the first approved therapy in combination with CT for 1L treatment of both sq. & non sq. NSCLC in China          

Click here to­ read full press release/ article 

Ref: PRNewswire | Image: Merck


Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions